Characteristics of Patients Enrolled in Sentinel Surveillance for Severe Acute Respiratory Infection by Viral Influenza Result, Egypt, November 2007-November 2014.

<p>Characteristics of Patients Enrolled in Sentinel Surveillance for Severe Acute Respiratory Infection by Viral Influenza Result, Egypt, November 2007-November 2014.</p

Percentage of Season’s Influenza-Positive Specimens by Month, Egypt, July 2008-June 2014.

<p>The percentage of each season’s influenza-positive specimens occurring in each month of the influenza season is displayed. Influenza seasons were defined as the one-year period from July to June.</p

Factors Associated with Death among Influenza-Positive Patients Enrolled in Sentinel Surveillance for Severe Acute Respiratory Infection, Egypt, November 2007-November 2014.

<p>Factors Associated with Death among Influenza-Positive Patients Enrolled in Sentinel Surveillance for Severe Acute Respiratory Infection, Egypt, November 2007-November 2014.</p

Proportion of positive samples for each viral respiratory pathogen by month.

<p>Proportion of positive samples out of total samples tested for each pathogen are shown.</p

Proportion of tested SARI cases positive for viral respiratory pathogens (influenza, RSV, AdV, hMPV, hPIV1, hPIV2, hPIV3) by country, year, age and sex.

<p>Proportion of tested SARI cases positive for viral respiratory pathogens (influenza, RSV, AdV, hMPV, hPIV1, hPIV2, hPIV3) by country, year, age and sex.</p

Univariate and multivariate logistic regression examining predictors of severe outcomes.

<p>Includes only individuals for whom testing for the full panel of viral respiratory viruses was performed and for whom data on demographics and clinical risk factors are complete. Severe outcome is defined as illness requiring ventilation or intensive care or resulting in death.</p

Coinfections by viral respiratory pathogen (n = 501).

<p>Includes 5 patients with influenza, RSV and AdV; 3 with influenza, RSV and hMPV; 3 with RSV, AdV and hMPV; 3 with RSV, AdV and hPIV1; 2 with RSV, AdV and hPIV3; 2 with AdV, hMPV and hPIV3; 1 with influenza, AdV and hMPV; 1 with RSV, AdV and hPIV2; 1 with RSV, hPIV1 and hPIV2; 1 with influenza, RSV, AdV and hMPV; 1 with RSV, AdV, hMPV and hPIV3; 1 with RSV, AdV, hPIV1 and hPIV3.</p

Indicators of severity of disease by pathogen (influenza, RSV, AdV, hMPV, PIV1, PIV2, PIV3 and any coinfection).

<p>Severe outcome is defined as illness requiring ventilation or intensive care or resulting in death. For each pathogen of interest, tested SARI patients with a positive result for that pathogen were compared to a reference group of tested SARI patients with a negative result for that pathogen. For “any coinfection”, tested SARI patients with any coinfection were compared to a reference group of tested SARI patients with test results for all pathogens of interest and no identified coinfection.</p